Bronchopulmonary Dysplasia (BPD)
27
5
6
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
3.7%
1 terminated out of 27 trials
90.0%
+3.5% vs benchmark
11%
3 trials in Phase 3/4
56%
5 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (27)
The Budesonide in Babies (BiB) Trial
Heterologous Cord Blood-Derived Red Blood Cell for Transfusion in Extremely Preterm Infants
Impact of the Early Life Virome Development on Bronchopulmonary Dysplasia in Preterm Neonates
PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysplasia
Can Betamethasone Given After Birth Help Extremely Premature Babies Come Off Breathing Support Safely and Effectively?
Characterization of Extracellular Vesicles From the Cord Blood of Extremely Preterm New Borns and Their Correlation With Severe Morbidity and Mortality
Continued Pressure for Alveolar Protection (CPAP Trial)
National Surveillance and Prevention of Neonatal VAP
Combined Oscillation-Volume guarantEe Study
Metformin for Premature Infants With Bronchopulmonary Dysplasia
Dexamethasone Regimens for BPD Prevention in Preterm Infants
Long-Term Burden of BPD and Health-Related Quality of Life (BronQ Family)
Transfusion of Prematures Trial
The Correlation Between Red Cell Transfusion and Complications of Prematurity
Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants
Chloride Imbalance in Preterm Infants
Steroids and Surfactant in Extremely Low Gestation Age Infants Dose Escalation Trial
Overview: Use of Respiratory Support At Home in Children
Enhancing Lung Health in Kids With Structural Lung Damage and Malformations: Azithromycin (AZI) for Airway Infection Prevention
Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)